Astrue resigns from Epix

May 7, 2006

MRI contrast developer Epix Pharmaceuticals interim CEO Michael Astrue has resigned.

Astrue, who became interim CEO in September 2005, will serve as a consultant to the Cambridge, MA-based firm until July 31. Following the completion of Epix's planned merger with Predix Pharmaceuticals, Predix president and CEO Dr. Michael Kauffman will become CEO of the combined company.

Current Epix president Dr. Andrew Uprichard will remain in that role, Epix said.

By AuntMinnie.com staff writers
May 8, 2006

Related Reading

Epix to buy Predix Pharmaceuticals, April 3, 2006

Epix adds VPs, February 23, 2006

Sales fall, losses grow for Epix in ’05, February 16, 2006

Schering options joint Epix-Schering agent, February 13, 2006

Epix lawsuit dismissed, February 2, 2006

Copyright © 2006 AuntMinnie.com

Contrast Injector

Ferumoxytol-enhanced MRA is safe for chronic kidney disease patients

January 29, 2025

Ultrafast and standard MRI in a 30-year-old woman with triple-negative invasive ductal carcinoma. (A) Ultrafast MRI taken 16.8 seconds after contrast agent injection. (B) Standard MRI taken 58.8 seconds after contrast agent injection. Both images show an oval-shaped, irregular marginated, rim-enhancing mass in the left outer breast. For 3D tumor segmentation, the entire enhanced tumor margins were drawn from top to bottom of each tumor in axial views of U2 phase postcontrast ultrafast MRI and the initial phase postcontrast standard MRI. Among the 14 ultrafast images, U1 is the first phase in which the signal intensity of the hotspot region of interest of the tumor is 10% higher than the average signal intensity of unenhanced images. U2 is the immediate next phase of U1 and the well-established tumor enhancement time.

Ultrafast MRI exam bests standard MRI for classifying breast cancers

January 28, 2025

Echelon Synergy 1.5T MRI with MotionClear Comprehensive Motion Correction Suite

Echelon Synergy 1.5T MRI with MotionClear Comprehensive Motion Correction Suite

January 1, 2025

Brain MRI tracks risk of stage IV breast cancer metastases

January 24, 2025

Ferumoxytol-enhanced MRA is safe for chronic kidney disease patients

By Kate Madden Yee

Ferumoxytol-enhanced MR angiography (MRA) appears to be safe for chronic kidney disease patients, researchers have reported.

January 29, 2025

Contrast Injector

Ultrafast MRI exam bests standard MRI for classifying breast cancers

By Amerigo Allegretto

An ultrafast MRI-based radiomics exam performs just as well as standard MRI and isn’t dependent on radiologist experience.

January 28, 2025

Ultrafast and standard MRI in a 30-year-old woman with triple-negative invasive ductal carcinoma. (A) Ultrafast MRI taken 16.8 seconds after contrast agent injection. (B) Standard MRI taken 58.8 seconds after contrast agent injection. Both images show an oval-shaped, irregular marginated, rim-enhancing mass in the left outer breast. For 3D tumor segmentation, the entire enhanced tumor margins were drawn from top to bottom of each tumor in axial views of U2 phase postcontrast ultrafast MRI and the initial phase postcontrast standard MRI. Among the 14 ultrafast images, U1 is the first phase in which the signal intensity of the hotspot region of interest of the tumor is 10% higher than the average signal intensity of unenhanced images. U2 is the immediate next phase of U1 and the well-established tumor enhancement time.

63% of heavy cannabis users show reduced working memory ability

By Kate Madden Yee

Functional MRI reveals that 63% of heavy lifetime cannabis users show reduced brain activity during a working memory task -- and that 68% of recent users also show this impact.

January 28, 2025

Cannabis Marijuana

Brain MRI tracks risk of stage IV breast cancer metastases

By Kate Madden Yee

Brain MRI shows promise for surveilling women at risk for asymptomatic stage IV breast cancer metastases by tracking molecular subtypes of the disease.

January 24, 2025

MR spectroscopy reveals neurochemical patterns linked to COVID-19

By Kate Madden Yee

Proton MR spectroscopy (MRS) reveals "remarkable" neurochemical patterns associated with COVID-19-induced anosmia, or loss of smell.

January 23, 2025

Simulated contrast-enhanced MRI helps assess prostate cancer

By Kate Madden Yee

Simulated contrast-enhanced MR images from noncontrast sequences using deep learning show promise for assessing clinically significant prostate cancer.

January 15, 2025

2025 01 14 Radiology Huang Figure5 Thumbnail

Measuring myelin volume with synthetic MRI helps predict stroke outcomes

By Kate Madden Yee

Stroke patients with large total myelin volume measured on synthetic MR imaging appear to have good functional outcomes on follow-up.

January 15, 2025

ML model using CCTA, MRI data predicts MACE in cardiac patients

By Amerigo Allegretto

A machine-learning (ML) model that includes both CCTA and stress cardiac MRI data can accurately predict major adverse cardiovascular events (MACE).

January 14, 2025

Heart Valves 3 D Base Thumbnail

Genetic testing, risk assessment tied to more breast MRI uptake

By Amerigo Allegretto

Women with high-risk pathological variants for breast cancer as identified by genetic testing and risk assessment are more likely to undergo breast MRI.

January 13, 2025

Deep-learning model based on MRI data predicts prostate cancer risk

By Kate Madden Yee

A deep-learning model based on MRI and clinical parameters appears effective for predicting the risk of prostate cancer progression.

January 10, 2025

Prostate Cancer 3 D Rendering

Breast MRI surveillance reduces disease recurrence

By Kate Madden Yee

In women with a personal history of breast cancer, postoperative MRI surveillance appears to lower their odds of advanced second breast cancer.

January 7, 2025

Mri Breast Cancer

Women with BRCA1/2 germline mutations are often denied breast MRI

By Kate Madden Yee

Women with BRCA1/2 germline mutations are often denied breast MRI -- despite the fact that the exam is recommended for this population.

January 3, 2025

Mri Breast Cancer

Page 1 of 612